Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants - Wikidata - awgldk - TriplyDB

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants

http://www.wikidata.org/entity/Q33776950

about

Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics Cardiovascular pharmacogenomics: current status and future directions OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies Differential Gene Expression across Breed and Sex in Commercial Pigs Administered Fenbendazole and Flunixin Meglumine Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study Xenobiotic, bile acid, and cholesterol transporters: function and regulation.Synergistic interaction between genetics and disease on pravastatin disposition SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group Genetic variation in drug transporters in ethnic populations.Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.Impact of OATP transporters on pharmacokinetics.The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis.Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR.Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance Dyslipidemia in special ethnic populations Functional characterization of liver enhancers that regulate drug-associated transporters.Pharmacogenomics of membrane transporters: past, present and future Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.Organic anion uptake by hepatocytes.Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.Transporter pharmacogenetics and statin toxicity.Interethnic Variation in Lipid Profiles: Implications for Underidentification of African-Americans at risk for Metabolic Disorders.Molecular aspects of microcystin-induced hepatotoxicity and hepatocarcinogenesis.Drug transport by breast cancer resistance protein.The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.

P2860

Q24596022-6846B1BC-2252-4548-BED4-E7ED3318C5BD Q26786582-D5EA0421-97CD-43EB-AB2E-8F0FE3D6A8AB Q26801183-C62267BE-4509-428E-873F-822254A43DB0 Q27001267-6A33A2DA-6AED-49B1-BE38-36DB58D84444 Q27318232-1D50AF88-F8E6-4934-8121-D456A59ED7E2 Q28240269-42BDFEBC-6C8D-4F60-9553-591382EAEC05 Q33530066-B3A6EFB4-A4E2-4321-9E82-4B18436AD62F Q33714593-1993EF0A-F264-4BAA-813F-86572B6FBA77 Q33786577-4505CEB2-305F-47B7-B143-32E731E463AC Q34047278-B894716D-6B27-42CB-B3A9-A0D4BD478552 Q34292537-2421B8C9-AA04-49EE-A2B2-B255A7A5183C Q34571070-DC3CB9B8-4B22-48C7-9058-64B86D544BE5 Q34603829-1A66D25D-7F9D-4669-9AD8-4E5D46B36315 Q34612244-F605B972-FE05-44EB-AD61-B5643FD9C77E Q34613443-14D4740F-0CA4-4A7B-B499-FC2D7111BB3C Q35113316-2E15228B-DB8D-48A3-AD9B-4242AA7237E2 Q35188657-865E6DB4-F8BD-458D-9F0C-7CB9176D20D7 Q35234128-B5657833-1595-4FCC-B511-72BBC58D3593 Q35375045-A32BABE2-3155-4744-BF43-6CB1CEACAAC2 Q35573543-DE0BCBFF-9830-44E8-BA1A-FCA2CCDF4C60 Q35583006-4398FAF4-9DB3-4A4D-B296-9337145AFC33 Q35603055-C57BF064-80EB-44C8-BBF1-F5303DFE7D67 Q35689076-C20C05A0-A561-4136-82F8-597658D5F33C Q36111214-3AEBA456-C707-4CE5-AA0E-BF92006452CE Q36803379-D0903CAB-2D05-4525-BAF1-3EF67739A8E8 Q36808178-2E3FA193-9570-4575-9436-B1C76B96B5D0 Q36877910-BE9DE7E6-0AE7-4C8B-8B13-CC2B842FC8FF Q36926314-D22D032B-349B-4FF4-B68B-9D18675EC5DF Q37120923-FDFED4DB-9C48-4F74-9B4D-391C2D7CD499 Q37137527-F6F4A3A8-D8E7-4108-A80D-86ACCEB8F661 Q37279044-3AF14ABB-34DE-4CDB-B159-12A911C23AB0 Q37474395-31155AD0-2F7D-43D4-8272-DC8FD6F438CA Q37481450-C0710B9D-C759-4478-A64A-08D735686639 Q37579733-B29F658C-C6CD-44A5-96A6-98DE94B76F73 Q37627544-A9575EAC-7AB4-4493-AE49-F97953D83D2A Q37632780-C4DA57C3-C027-46F0-B7C4-BDF4D4F8E52B Q37730716-93F738B3-0339-4810-8123-03A31C9F1FC1 Q37793056-96173DBA-1A87-4526-816C-0CD7D6A77432 Q37810986-DAD94AF3-E354-43EF-BC60-B9FA0B45D902 Q37855801-5CE28CF1-CF70-4CAE-BAAC-3B7910233E93

P2860

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants

http://www.wikidata.org/entity/Q33776950

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Effect of drug transporter gen ...... African-American participants

@ast

Effect of drug transporter gen ...... African-American participants

@en

type

label

Effect of drug transporter gen ...... African-American participants

@ast

Effect of drug transporter gen ...... African-American participants

@en

prefLabel

Effect of drug transporter gen ...... African-American participants

@ast

Effect of drug transporter gen ...... African-American participants

@en

P1433

Q33776950-0CEE97E6-9CD3-41F2-ABFC-470A17FD4403

P1476

Q33776950-FBEDCA87-7EB8-4E85-9F3C-A6C94757D038

P2093

Q33776950-27735215-69AD-4648-AAE9-509ADF46A165

Q33776950-4C8F98B5-9C9D-47B2-B924-C3589EC4837E

Q33776950-79695345-1E7A-4343-8DDD-4625522C2CB3

Q33776950-8221B19F-EE38-4343-88E5-ABF7818C545C

Q33776950-83B05AE8-83DE-4344-BC0B-F18774AE2FDA

Q33776950-BB24284F-1B4F-4FC8-A988-A59DB96291DE

Q33776950-CDA91B21-EEA1-471D-9089-D8387F9DF749

Q33776950-D8E0BECF-2A68-4F03-8C41-F3ACA3D911E5

P2860

Q33776950-0C7AAA92-23DD-4DBC-8C6B-39DDC770A642

Q33776950-1CC67D83-8017-4F61-9E27-223FA1CF3B13

Q33776950-1DCF2ADF-80AF-46E4-9FD0-AF8DA6F411B5

Q33776950-1F072848-EBD0-4013-9F0F-24FA4C7B799F

Q33776950-33E52F2A-A20B-4060-96E8-F27954FDB246

Q33776950-3EF3C921-F425-462C-853D-F576D4DBCE06

Q33776950-45AB3BE9-31ED-43F6-B4DF-22A862B8C732

Q33776950-52CDA2F2-2814-44CF-85A2-ECA61AA25958

Q33776950-5AE6C43A-A474-4A96-93E4-4DBB23E74389

Q33776950-5CA7BDC7-1121-4D8B-8C27-AF3103AC43DB

P304

Q33776950-9B2BEE32-0978-43BC-9E34-892F5FC016D3

P31

Q33776950-3A388F9C-93D7-4D37-80E7-674C09C1D201

P356

Q33776950-B9B974F9-9B0D-4B7C-8124-843C2D7EB6FF

P433

Q33776950-74EC01F7-A163-477D-BAD4-50FF2183DF1E

P478

Q33776950-5F849141-2B03-4CB8-BDBB-F7EBD4DEF4BF

P50

Q33776950-AE70B645-3BF8-43EF-BB32-CE2543B31A64

P577

Q33776950-641519A1-73DA-4497-8BF1-4AA214F1379F

P698

Q33776950-C9F1AE2C-B51F-499E-9C95-CCA2BC8FC823

P932

Q33776950-773EB31B-15BD-4E0C-A435-EF40DF74F138

P356

FPC.0B013E3280EF698F

P1433

Pharmacogenetics and Genomics

P1476

Effect of drug transporter gen ...... African-American participants

@en

P2093

C Michael Stein

http://www.w3.org/2001/XMLSchema#string

David G Bailey

http://www.w3.org/2001/XMLSchema#string

Gail Mayo

http://www.w3.org/2001/XMLSchema#string

Leena Choi

http://www.w3.org/2001/XMLSchema#string

Richard B Kim

http://www.w3.org/2001/XMLSchema#string

Richard H Ho

http://www.w3.org/2001/XMLSchema#string

Rommel G Tirona

http://www.w3.org/2001/XMLSchema#string

Ute I Schwarz

http://www.w3.org/2001/XMLSchema#string

P2860

A New Statistical Method for Haplotype Reconstruction from Population Data

A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters

Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties

Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis

A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter

Genetic factors related to unconjugated hyperbilirubinemia amongst adults

P304

647-656

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E3280EF698F

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17622941

http://www.w3.org/2001/XMLSchema#string

P932

4063287

http://www.w3.org/2001/XMLSchema#string